Strategic considerations as Korea prepares for new patent term extension system

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Strategic considerations as Korea prepares for new patent term extension system

Sponsored by

hanolip-400px.png
Sunrise in Seoul, South Korea

Min Son of Hanol IP & Law explains that the regime will limit extensions to one patent per approval and cap extended periods at 14 years from the date of marketing authorisation

A new patent term extension (PTE) system will be implemented in South Korea starting July 22 2025. The extension will be capped at 14 years from the date of marketing approval (MA), and the number of patents that can be extended will be limited to one. This new regulation applies to PTE applications filed on or after July 22 2025.

Background

Unlike other jurisdictions such as the US, Europe, and China, Korea has previously allowed PTEs without a 14- or 15-year time limit from the date of MA and for multiple patents involved in a single MA. However, concerns have been raised that this broad protection delays generic entry and limits public access to affordable medicines. The latest revisions to the Patent Act are aimed at addressing this issue.

Fourteen-year cap from the date of MA

In Korea, the length of an extension corresponds to the period during which a patented invention covering a drug or agrochemical product could not have been practised after the patent issuance due to the MA for the product.

In practice, the length of the extension is calculated as the sum of:

  • The time taken for domestic clinical trials (i.e., clinical trials conducted with the approval of the Korean regulatory authorities); and

  • The time taken for regulatory approval review, except for periods occurring before the date of patent issuance.

Any delay attributable to the MA holder (such as a data supplementation period) is excluded from the extendible period. The maximum five-year extension is available.

Under the amended Patent Act, there is no change in the calculation practice mentioned above, but an additional limitation applies: the total extension cannot exceed 14 years from the date of MA (Article 89(1) of the Patent Act).

The following hypothetical example, where the total extension exceeds 14 years from the date of MA, explains that the extended expiry date will be shortened under the amended Patent Act.

Hanol graphic.png

In cases where the extensions expire within 14 years from the date of MA, there is no reduction due to the 14-year cut-off.

Meanwhile, if a patent has an original expiry date that is more than 14 years from the date of MA, the patent is not eligible for a PTE.

Violating the new limitation will constitute grounds for rejection or invalidation. PTE applicants can resolve this issue by correcting the extension period voluntarily or when responding to the examiner’s office action.

Only one patent extension per approval

Korea now has the following limitations on PTE granting:

  • A PTE is granted only once per patent;

  • If there are multiple MAs for multiple active ingredients covered by a single patent, a PTE is granted only once for the patent, based on one selected from the multiple MAs; and

  • If there are multiple MAs for the same active ingredient, a PTE is granted only once for a single patent, based solely on the first MA.

Under the previous system, if multiple patents are involved in a single MA, there was no limitation on the number of patents eligible for a PTE, so all the patents could benefit from a PTE.

Now, under the amended system, a new limitation is added: only one patent is eligible for a PTE per approval (Article 90(7) of the Patent Act). Violating the new limitation will constitute grounds for rejection or invalidation. Thus, PTE applicants must ultimately elect one patent for the extension.

The decision to elect a patent for a PTE can be made before the PTE filing deadline, which is three months from the date of MA. Alternatively, this decision can be postponed after filing PTE applications for multiple patents until the issuance of the examiner’s office action for violating this limitation. When deciding this, the patent holders will need to make strategic considerations to maximise the PTE.

Strategic considerations

Under the new system, it is important to decide which patent to extend. Many factors need to be considered, such as:

  • Which patent can ensure the longest patent term within the 14-year cap;

  • Which patent is the strongest or most vulnerable against validity challenges;

  • Which patent is the easiest to enforce;

  • The subject matter (product claim versus method claim);

  • The scope of the patent; and

  • Whether the patents are primary or secondary patents.

For example, let us assume that there are four patents involved in a drug product X for which MA is expected to be obtained on July 26 2025. Their calculated PTE days and final expiry dates are shown in the table below.

 

Claimed subject matter

Patent Cooperation Treaty filing date

Original expiry date

Calculated PTE

(days)

Projected final expiry date

Elect?

Date of issuance

Patent 1

(P1)

Compound A

 

17/1/2017

17/1/2037

1,031

14/11/2039

> 14-year cap

= 26/7/2039

Yes

11/10/2021

Patent 2

(P2)

Medicament for treating disease Y comprising compound A

20/2/2018

20/2/2038

478

13/6/2039

< 14-year cap

No

28/12/2023

Patent 3

(P3)

Sustained release formulation comprising compound A

19/5/2019

19/5/2039

246

20/1/2040

> 14-year cap

= 26/7/2039

No

16/8/2024

Patent 4

(P4)

Medicament for treating disease Y in a specific patient population with a specific dose, comprising compound A

20/5/2020

20/5/2040

> 14-year cap

0

N/A

No

10/1/2025


First, the 14-year cap is July 26 2039, and the maximum extension may therefore be until July 26 2039. Any patents with original expiry dates later than the 14-year cap should be excluded, since they are not eligible for a PTE (e.g., P4 in the above table).

In the above cases, while various factors should be considered, selecting the one claiming the product (e.g., P1) might be a safe approach, as product claims are generally easier to defend and enforce.

Meanwhile, under the new rule of one patent extension per one approval, it is still important to file divisional applications if a parent application covers multiple drug candidates so as to ensure that a PTE can be filed for each potential active ingredient. Furthermore, to maximise a PTE, using an accelerated examination may be a strategic approach because only the non-working period (of the domestic clinical trial and regulatory review) ‘after’ the date of patent issuance is counted for a PTE.

more from across site and SHARED ros bottom lb

More from across our site

The Getty Images v Stability AI case, which will hear untested points of law, is a reminder of the importance of the legal system and the excitement it can generate
Firms explain the IP concerns that can arise amid attempts by brands to show off their ‘Canadianness’ to consumers
Counsel say they will be monitoring issues such as the placement of house marks, and how Mondelēz demonstrates a likelihood of confusion in its dispute with Aldi
The EUIPO expanding its mediation services and a new Riyadh office for Simmons & Simmons were also among the top talking points this week
David Boundy explains why Pierson Ferdinand provides a platform that will allow him to use administrative law to address IP concerns
Developments included an anti-anti-suit injunction being granted for the first time, and the court clarifying that it can adjudicate over alleged infringements that occurred before June 2023
Griffith Hack’s Amanda Stark, one of our ‘Top 250 Women in IP’, explains how peer support from male colleagues is crucial, and reveals why the life sciences sector is thriving
The case, which could offer clarity on the training of AI models within the context of copyright law, will go to trial in the UK next week
CMS IndusLaw co-founder Suneeth Katarki says he plans to hire a patent team in India and argues that IP should play a major role within full-service firms
Partners at the firm explain why they’ve seen more SEP cases at the ITC, and why they are comfortable recommending the forum to clients
Gift this article